Roche: FDA Approves Subcutaneous Formulation Of Actemra For Active PJIA

Roche Holding AG (RHHBY) said that the U.S. Food and Drug Administration has approved the subcutaneous or SC formulation of Actemra, or tocilizumab, for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older.

from RTT - Biotech https://ift.tt/2Iht9Ws
via IFTTT